A carregar...
Pioglitazone, a PPARγ agonist, attenuates PDGF-induced vascular smooth muscle cell proliferation through AMPK-dependent and AMPK-independent inhibition of mTOR/p70S6K and ERK signaling
Pioglitazone (PIO), a PPARγ agonist that improves glycemic control in type 2 diabetes through its insulin-sensitizing action, has been shown to exhibit beneficial effects in the vessel wall. For instance, it inhibits vascular smooth muscle cell (VSMC) proliferation, a major event in atherosclerosis...
Na minha lista:
| Publicado no: | Biochem Pharmacol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4753090/ https://ncbi.nlm.nih.gov/pubmed/26643070 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcp.2015.11.026 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|